90 related articles for article (PubMed ID: 35489393)
1. The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer.
Du YB; Wang XF; Liu XJ; Li Y; Miao QF; Jiang M; Sheng WJ; Zhen YS
Biochem Pharmacol; 2022 Jul; 201():115057. PubMed ID: 35489393
[TBL] [Abstract][Full Text] [Related]
2. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
3. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
5. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
8. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.
Zhu BY; Shang BY; Du Y; Li Y; Li L; Xu XD; Zhen YS
Oncotarget; 2017 Feb; 8(9):14748-14758. PubMed ID: 28107195
[TBL] [Abstract][Full Text] [Related]
9. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
11. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.
Gong J; Xie J; Bedolla R; Rivas P; Chakravarthy D; Freeman JW; Reddick R; Kopetz S; Peterson A; Wang H; Fischer SM; Kumar AP
Clin Cancer Res; 2014 Mar; 20(5):1259-73. PubMed ID: 24520096
[TBL] [Abstract][Full Text] [Related]
13. Glial cell line-derived neurotrophic factor enhances nuclear factor-kappaB activity and invasive potential in human pancreatic cancer cells.
Takahashi H; Funahashi H; Sawai H; Sakamoto M; Matsuo Y; Yamamoto M; Okada Y; Hayakawa T; Manabe T
Pancreas; 2004 Jul; 29(1):22-7. PubMed ID: 15211107
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.
Tao HY; He SM; Zhao CY; Wang Y; Sheng WJ; Zhen YS
Int J Biol Macromol; 2023 Jan; 226():1088-1099. PubMed ID: 36435475
[TBL] [Abstract][Full Text] [Related]
16. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts.
Mohammad RM; Banerjee S; Li Y; Aboukameel A; Kucuk O; Sarkar FH
Cancer; 2006 Mar; 106(6):1260-8. PubMed ID: 16475211
[TBL] [Abstract][Full Text] [Related]
19. A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in
Inoue A; Mizushima T; Wu X; Okuzaki D; Kambara N; Ishikawa S; Wang J; Qian Y; Hirose H; Yokoyama Y; Ikeshima R; Hiraki M; Miyoshi N; Takahashi H; Haraguchi N; Hata T; Matsuda C; Doki Y; Mori M; Yamamoto H
Mol Cancer Ther; 2018 May; 17(5):977-987. PubMed ID: 29545333
[TBL] [Abstract][Full Text] [Related]
20. Alizarin, a nature compound, inhibits the growth of pancreatic cancer cells by abrogating NF-κB activation.
Xu Z; Hou Y; Zou C; Liang H; Mu J; Jiao X; Zhu Y; Su L; Liu M; Chen X; Qian C; Zhu X; Gong W; Dong Q; Zhang F
Int J Biol Sci; 2022; 18(7):2759-2774. PubMed ID: 35541911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]